AMD vs Amgen: Founders, CEOs and History
AMD was founded in 1969 by Jerry Sanders, Edwin Turney and is led by Lisa Su. Amgen was founded in 1980 by George B. Rathmann, William K. Bowes Jr. and is led by Robert A. Bradway.
Company facts
Founders
AMD
Jerry Sanders
Advanced Micro Devices (AMD) was founded in May 1969 by Jerry Sanders, a charismatic, flamboyant electrical engineer, along with seven of his colleagues from Fairchild Semiconductor (the well-known incubator of Silicon Valley that also birthed Intel).
Edwin Turney
Edwin Turney helped establish the operating foundation behind AMD's early logic-device business. While Sanders became the public face, Turney's contribution was making sure the company could earn trust through production reliability and execution.
Amgen
George B. Rathmann
Amgen, originally incorporated as Applied Molecular Genetics, was founded in 1980 not by a single scientist, but by a calculated syndicate of venture capitalists and academics trying to commercialize the brand-new science of recombinant DNA.
William K. Bowes Jr.
William K. Bowes Jr. Was the venture capital strategist whose vision catalyzed Amgen's formation.
CEOs and their tenures
AMD
- Jerry Sanders1969–2002
CEO
Sanders, born in Chicago in 1936, worked at Douglas Aircraft and Motorola before joining Fairchild Semiconductor in 1961, where he rose to head worldwide sales and marketing.
Source - Hector Ruiz2002–2008
CEO
Ruiz grew up in Piedras Negras, Mexico, and as a teenager crossed the US border daily to attend high school in Eagle Pass, Texas, graduating valedictorian only three years after learning English.
Source - Dirk Meyer2008–2011
CEO
Meyer, a University of Illinois computer-engineering graduate with an MBA from Boston University, co-architected the Alpha 21064 and 21264 microprocessors at Digital Equipment Corporation before joining AMD in 1996, where he personally led development of the o…
Source - Rory Read2011–2014
CEO
Read spent 23 years at IBM in global leadership roles before becoming president and COO of Lenovo, and holds an information-sciences degree from Hartwick College.
Source - Lisa Su2014–present
CEO
Born in Taiwan and raised in the United States, Su earned bachelor's, master's and doctorate degrees in electrical engineering from MIT and worked at Texas Instruments, IBM and Freescale Semiconductor before joining AMD in 2012 as senior vice president of glob…
Source
Amgen
- George B. Rathmann1980–1988
Chief Executive Officer
George Rathmann, a physical chemist who had run research and development at Abbott Laboratories, was named Amgen's first chief executive in 1980 and worked from a small trailer so that laboratory space could go to scientists.
Source - Gordon M. Binder1988–2000
Chief Executive Officer
Gordon Binder joined Amgen as chief financial officer in 1982 and led its June 1983 initial public offering.
Source - Kevin W. Sharer2000–2012
Chief Executive Officer
Kevin Sharer joined Amgen in 1992 as president and chief operating officer and became chairman and chief executive in 2000.
Source - Robert A. Bradway2012–present
Chairman and Chief Executive Officer
Robert Bradway became chief executive on May 23, 2012, succeeding Kevin Sharer as the fourth CEO in Amgen's history, and added the chairmanship at the start of 2013.
Source
Timeline: AMD and Amgen side by side
1969AMD
Advanced Micro Devices Founded
Jerry Sanders and seven colleagues from Fairchild Semiconductor founded AMD on May 1, 1969, and broke ground that year on the 915 DeGuigne building in Sunnyvale, California, which remained the headquarters for more than 47 years.
1975AMD
Entry Into Microprocessors
AMD entered the microprocessor market in 1975, moving beyond the logic devices it started with. The decision put it into direct competition with Intel and made x86 compatibility the center of its business for the next four decades.
1980Amgen
Applied Molecular Genetics is incorporated
Applied Molecular Genetics (AMGen) was incorporated on April 8, 1980 in Thousand Oaks, California, as the idea of venture capitalist William K. Bowes Jr. and a group of scientific collaborators.
1983Amgen
Nasdaq listing and the erythropoietin clone
Amgen completed its initial public offering on June 17, 1983, raising nearly US$40 million under chief financial officer Gordon Binder, and formally shortened its name to Amgen.
1984Amgen
Kirin-Amgen joint venture formed
Amgen and Kirin Brewery Company of Japan formed Kirin-Amgen in 1984 as a joint venture for the worldwide commercialization of erythropoietin.
1985Amgen
G-CSF cloned, leading to Neupogen
While Fu-Kuen Lin's team worked on erythropoietin, researcher Larry Souza and his group cloned and expressed human granulocyte colony-stimulating factor in 1985.
1989Amgen
FDA approves Epogen
The FDA approved Epogen (epoetin alfa) on June 1, 1989 for anemia in patients with chronic kidney failure on dialysis. It was the first commercial recombinant human erythropoietin. Epogen's U.S.
1991Amgen
Neupogen approved, giving Amgen a second franchise
The FDA approved Neupogen (filgrastim) in February 1991. By stimulating white blood cell production it reduced the risk of infection in cancer patients with chemotherapy-induced neutropenia.
1991Amgen
Amgen wins the erythropoietin patent fight
On March 6, 1991 the U.S. Court of Appeals for the Federal Circuit upheld the Kirin-Amgen erythropoietin patent and ruled against Genetics Institute in Amgen v. Chugai Pharmaceutical and Genetics Institute.
1999AMD
Athlon Breakthrough
Athlon launched in 1999 and matched or beat Intel on desktop performance. In March 2000 AMD announced the first 1 GHz x86 processor, days ahead of Intel, which changed how enthusiasts and PC makers judged the company.
2001Amgen
FDA approves Aranesp, the longer-acting EPO
Aranesp (darbepoetin alfa), an erythropoietin analogue with modified glycosylation and a longer half-life, was approved in 2001. Less frequent dosing than Epogen improved convenience and gave Amgen a newer, higher-priced product to migrate patients toward.
2002Amgen
US$16 billion Immunex acquisition brings Enbrel in-house
Amgen completed its acquisition of Immunex Corporation on July 16, 2002, the largest biotechnology deal to that point at about US$16 billion in stock and cash.
2005AMD
Antitrust Lawsuit Against Intel
AMD sued Intel in 2005, alleging rebates and exclusionary practices that limited its access to PC makers.
2006AMD
ATI Technologies Acquired
AMD acquired ATI Technologies in 2006 for about $5.4B to add graphics and chipsets. The debt-funded deal strained the balance sheet just as Intel shipped Core 2, but ATI became the basis for Radeon graphics, console APUs, and later Instinct accelerators.
2009AMD
Fabless Pivot Through GlobalFoundries
AMD moved its manufacturing operations into GlobalFoundries in 2009 and stopped owning fabs. The change removed billions of annual capital spending and let AMD buy leading-edge capacity, but it also tied the product roadmap to outside foundries.
2010Amgen
Prolia and XGEVA create the bone health franchise
The FDA approved Prolia (denosumab) for postmenopausal osteoporosis in June 2010 and XGEVA, the same molecule at a higher dose, for prevention of skeletal-related events in cancer patients in November 2010.
2011AMD
Bulldozer Architecture Failure
Bulldozer traded single-thread performance for core count at a time when most software depended on per-core speed. Reviews were poor, PC maker confidence fell, and server share collapsed, which is what forced the clean-sheet Zen project.
2014AMD
Lisa Su Becomes CEO
AMD's board appointed Lisa Su president and CEO on October 8, 2014, succeeding Rory Read. She narrowed the company around high-performance computing and put the engineering budget behind the Zen CPU core rather than spreading it across incremental projects.
2017AMD
Ryzen, EPYC, and Chiplets Rebuild AMD
Zen reached the market in 2017 as Ryzen for desktops and EPYC for servers. Chiplet packaging over Infinity Fabric let AMD build high core-count parts from smaller dies, improving usable yield and giving it a cost structure Intel's monolithic designs could not…
2019Amgen
US$13.4 billion purchase of Otezla from Celgene
Amgen agreed in August 2019 to buy worldwide rights to Otezla (apremilast) from Celgene for US$13.4 billion in cash, or about US$11.2 billion net of the present value of US$2.2 billion of anticipated future cash tax benefits, and closed on November 21, 2019.
2020Amgen
Amgen joins the Dow Jones Industrial Average
Amgen replaced Pfizer in the Dow Jones Industrial Average on August 31, 2020, becoming one of the thirty components in the index. Inclusion recognized the scale Amgen had reached and added passive demand from Dow-tracking funds.
2022AMD
Xilinx Acquisition
AMD completed the Xilinx acquisition in February 2022. The all-stock deal was announced in October 2020 at about $35B and was worth roughly $49B at close.
2023Amgen
US$27.8 billion Horizon Therapeutics acquisition closes
Amgen completed the acquisition of Horizon Therapeutics plc on October 6, 2023 for US$116.50 per share in cash, an equity value of about US$27.8 billion, after settling FTC litigation with a behavioral consent decree.
2024Amgen
Imdelltra becomes the first T-cell engager for small cell lung cancer
The FDA granted accelerated approval to tarlatamab, sold as Imdelltra, on May 16, 2024 for extensive stage small cell lung cancer that has progressed on or after platinum-based chemotherapy.
2025AMD
ZT Systems Acquired and Its Factories Sold
AMD closed the ZT Systems purchase on March 31, 2025, paying $3.2B in cash plus 8.3 million shares for rack-scale AI systems design.
2025AMD
OpenAI Agrees to Deploy 6 Gigawatts of AMD GPUs
On October 6, 2025 AMD and OpenAI announced a multi-year agreement covering 6 gigawatts of AMD GPUs, starting with a 1 gigawatt Instinct MI450 deployment in the second half of 2026.
2025AMD
Record $34.6B Revenue
AMD reported FY2025 revenue of $34.6B, up 34%, with net income of $4.3B and a 50% gross margin.
2025Amgen
VESALIUS-CV extends the Repatha case to primary prevention
In November 2025 Amgen reported Phase 3 VESALIUS-CV results in more than 12,000 patients with atherosclerosis or diabetes but no prior heart attack or stroke.
2026AMD
Meta Agrees to Deploy Up to 6 Gigawatts of AMD GPUs
On February 24, 2026 AMD and Meta announced a multi-year agreement for up to 6 gigawatts of Instinct GPUs.
2026Amgen
Medicare price setting reaches Enbrel and Otezla
Enbrel's negotiated Medicare price under the Inflation Reduction Act took effect on January 1, 2026, after it was named in the first round of ten drugs selected for negotiation.
Acquisitions
AMD
- ZT Systems2025$4.9B
- Silo AI2024$665M
- Xilinx2022$49B
- Pensando Systems2022$1.9B
- ATI Technologies2006$5.4B
Amgen
- Horizon Therapeutics plc2023$27.8B
- ChemoCentryx, Inc.2022$3.7B
- Five Prime Therapeutics2021$1.9B
- Celgene Otezla Business2019$13.4B
- Onyx Pharmaceuticals, Inc.2013$10.4B
- DeCODE Genetics2012$415M
Questions about AMD vs Amgen
Who is the CEO of Advanced Micro Devices, Inc. and Amgen Inc.?
Advanced Micro Devices, Inc. is led by Lisa Su and Amgen Inc. is led by Robert A. Bradway. Both serve as the top executive responsible for the company's strategy, operations, and financial performance.
When was Advanced Micro Devices, Inc. founded vs Amgen Inc.?
Advanced Micro Devices, Inc. was founded in 1969 — 11 years before Amgen Inc., which was founded in 1980. Advanced Micro Devices, Inc.'s longer operating history gives it a deeper track record but also potentially more institutional inertia compared to the younger Amgen Inc..
How many employees does Advanced Micro Devices, Inc. have compared to Amgen Inc.?
Advanced Micro Devices, Inc. employs approximately 31,000 people, while Amgen Inc. employs approximately 31,500. Amgen Inc. has the larger workforce at 31,500 employees, compared to Advanced Micro Devices, Inc.'s 31,000. A higher headcount does not necessarily imply greater efficiency — it often reflects differences in business model (e.g., manufacturing vs. software).
Where are Advanced Micro Devices, Inc. and Amgen Inc. headquartered?
Both Advanced Micro Devices, Inc. and Amgen Inc. are headquartered in United States, meaning they operate under the same primary regulatory and tax environment.
Who founded Advanced Micro Devices, Inc. and Amgen Inc.?
Advanced Micro Devices, Inc. was founded by Jerry Sanders, Edwin Turney. Amgen Inc. was founded by George B. Rathmann, William K. Bowes Jr..
Which company has a longer operating history — Advanced Micro Devices, Inc. or Amgen Inc.?
Advanced Micro Devices, Inc. has been operating for approximately 57 years, making it the more established of the two companies. Amgen Inc. has been in operation for around 46 years. A longer operating history often signals greater institutional resilience and brand recognition, though it can also mean slower adaptation to new market conditions.
Figures come from each company's filings and the sources linked beside them. Amounts reported in another currency are shown in US dollars at an approximate rate and marked with ~. Back to the AMD vs Amgen overview